Journal profile · CARDIAC & CARDIOVASCULAR SYSTEMS

Therapeutic Advances in Cardiovascular Disease

ISSN 1753-9447 · eISSN 1753-9455 · SAGE Publishing · United Kingdom

Therapeutic Advances in Cardiovascular Disease: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.3 (journal website); fully open access; APC about USD 2,650; review about 9 weeks (community reports); acceptance rate 22.2% (journal website); 14 articles in 2025; indexed in ESCI and Scopus.

Impact factor3.3From the journal's website, latest value
CAS zoneZone 3 · Medicine2025 upgraded edition, major category · 2026 Xinrui edition Zone 3 · Medicine
Review timeabout 9 weeksCommunity average
APCUSD 2,650Fully open access
Acceptance22.2%From the journal's website
Articles per year142025 · OpenAlex count

Scope

Aims, scope and focus

Therapeutic Advances in Cardiovascular Disease is published by SAGE Publishing and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Blood Pressure and Hypertension Studies, Heart Failure Treatment and Management and Coronary Interventions and Diagnostics, together about 23.7% of its articles. Its main subfields are Cardiology and Cardiovascular Medicine. (generated from OpenAlex topic counts and CAS ranking data)

Therapeutic Advances in Cardiovascular Disease is a peer-reviewed, gold open access journal dedicated to publishing clinically relevant research that informs cardiovascular disease prevention, diagnosis, treatment choices, therapeutic … | View full journal description This journal is a member of the Committee on Publication Ethics (COPE).

From the journal's Aims & Scope

Research area (LetPub): CARDIAC & CARDIOVASCULAR SYSTEMS

Editorial board by country: 2 in mainland China (about 5%); most named United States 17, United Kingdom 5, Italy 4, Spain 4, Mainland China 2 (43 members with a country) Editorial board ↗Publisher website ·

Main research topics OpenAlex counts of recent articles; shares are approximate

  1. Blood Pressure and Hypertension StudiesMedicine11.7%
  2. Heart Failure Treatment and ManagementMedicine6.3%
  3. Coronary Interventions and DiagnosticsMedicine5.8%
  4. Atrial Fibrillation Management and OutcomesMedicine5.6%
  5. Renin-Angiotensin System StudiesMedicine5.5%
  6. Acute Myocardial Infarction ResearchMedicine4.8%
  7. Cardiovascular Function and Risk FactorsMedicine4.5%
  8. Lipoproteins and Cardiovascular HealthMedicine4.3%

Rankings & indexing

CAS ranking and database indexing

CAS Journal Ranking

CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
LevelCategoryZone
MajorMedicineZone 3
MinorCardiac & Cardiovascular SystemsZone 4

Top journal: noReview journal: no

CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
LevelCategoryZone
MajorMedicineZone 3
MinorCardiac & Cardiovascular SystemsZone 4

Top journal: noReview journal: not marked

CAS Journal Ranking, previous upgraded edition (December 2023)Not covered

Not covered by this edition.

Database indexing

ESCIScopusDOAJLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Metrics

Impact metrics and publication volume

Impact

Impact factor (publisher)
3.3Publisher website ·
5-year impact factor (publisher)
3Publisher website ·
CiteScore 2026-06
4.6LetPub ·
SJR 2026-06
0.86LetPub ·
SNIP 2026-06
0.94LetPub ·
h-index
49OpenAlex ·
i10-index
289OpenAlex ·
2-year mean citedness
4.16OpenAlex ·
Self-citation rate
0%LetPub ·
Share of gold OA articles
100%LetPub ·

Volume

Articles per year
9LetPub ·
Articles per year (publisher)
3Publisher website ·

Articles by year OpenAlex count · 534 in total · the current year is incomplete

YearArticlesOpen accessCitations
202622228
2025141419
20242828239
20231717163
20221313131
20211010191

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Review & acceptance

Review time and acceptance

Average review time (community reports)
about 9 weeksLetPub ·
Acceptance rate (publisher)
22.2%Publisher website ·
Submission to first decision
11 daysPublisher website ·
Acceptance to publication
33 daysPublisher website ·
Submission to publication (journal-reported)
about 9 weeksDOAJ ·
Peer review
Single anonymous peer reviewDOAJ

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

Fees & open access

APC and open-access policy

Fully open accessDOAJ

Every article is open access; authors usually pay an article processing charge (APC).

SourceAPCFee waiverLicenseObserved
DOAJUSD 2,650YesCC BY, CC BY-NC
OpenAlexUSD 2,650——
LetPubUSD 2,650Yes—
Publisher websiteUSD 3,200 / USD 5,000——

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Submission

Article types and submission policies (journal website)

Article types accepted8
  1. original articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
  2. original articlesOriginal Articles. The Editors will consider clinical interventional and observational studies with clearly stated aims, well-reported methodology (including ma…Length not stated
  3. original research articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
  4. perspectiveView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
  5. reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
  6. review articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
  7. scoping reviewsScoping Reviews. These reviews assess the scope of available literature on a topic through comprehensive synthesis.Length not stated
  8. systematic reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
Publisher website
Policy excerpts from the journal's websiteAuthorship, Data availability, Publication ethics, Open access, Peer review, Plagiarism, Preprints, Trial registration / reporting guidelines
Authorship Author contributions

You will be asked to list the contribution of each author as part of the submission process. Please include the Author Contributions heading within your submission after the Acknowledgements section. The information you give on submission will then show under the Author Contributions heading later at the proofing stage.

Source ↗Publisher website ·
Data availability Data availability

Data policy: Authors are encouraged to share research data in a relevant public data repository, include a data availability statement, and cite the data. Model summary

The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…

Source ↗Publisher website ·
Publication ethics Ethical considerations

COPE membership: This Journal is a member of the Committee on Publication Ethics. Model summary

Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…

Source ↗Publisher website ·
Open access Publishing fees and open access

Therapeutic Advances in Cardiovascular Disease is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable to cover the cost of pu…

Source ↗Publisher website ·
Peer review Peer review policy

The following summary describes the peer review process for this journal: Identity transparency: Single-anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…

Source ↗Publisher website ·
Plagiarism Plagiarism

The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.

Source ↗Publisher website ·
Preprints Preprints

Preprint policy: The journal will consider submissions of manuscripts that have been posted on preprint servers. Authors should enter the preprint DOI when submitting and inform the editorial office. Updated versions should not be posted during peer review. Model summary

The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…

Source ↗Publisher website ·
Trial registration / reporting guidelines Clinical trial registration

The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

Source ↗Publisher website ·

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Profile

Publication details and official links

Publisher
SAGE Publishing
Country or region
United Kingdom
Language
English
ISSN
1753-9447
Electronic ISSN
1753-9455
Official links

FAQ

Frequently asked questions about Therapeutic Advances in Cardiovascular Disease

What CAS zone is Therapeutic Advances in Cardiovascular Disease in?

In the 2025 upgraded edition of the CAS Journal Ranking, Therapeutic Advances in Cardiovascular Disease is in Zone 3 of Medicine, and in Zone 4 of the minor category Cardiac & Cardiovascular Systems. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.

What is the impact factor of Therapeutic Advances in Cardiovascular Disease?

The journal's website gives an impact factor of 3.3; this is the journal's own figure, as LetPub lists none for it; CiteScore 4.6, h-index 49.

How long does peer review take at Therapeutic Advances in Cardiovascular Disease?

Authors report an average review time of about 9 weeks; the journal's website gives an acceptance rate of 22.2%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.

Where are the editorial board members of Therapeutic Advances in Cardiovascular Disease based?

Of the 43 board members whose country the journal's board page names, 2 (about 5%) are in mainland China; the countries named most often are United States (17), United Kingdom (5) and Italy (4). Counted from the institutions listed on the board page; for reference only.

Which databases index Therapeutic Advances in Cardiovascular Disease?

According to LetPub and DOAJ records, Therapeutic Advances in Cardiovascular Disease is indexed in ESCI, Scopus and DOAJ.

Is Therapeutic Advances in Cardiovascular Disease open access, and what is the APC?

Therapeutic Advances in Cardiovascular Disease is a fully open-access journal. APC about USD 2,650.

Sources and updates

The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .